echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > FDA approves Revlimid and rituxima combination therapy for the treatment of adults with flistic lymphoma or marginal lymphoma

    FDA approves Revlimid and rituxima combination therapy for the treatment of adults with flistic lymphoma or marginal lymphoma

    • Last Update: 2020-06-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, the United StatesFDA(http://has approved Revlimid (Linamine) and rituximab combination therapy (R2) for adult stoic patients with previously treated flicosive lymphoma (FL) or marginal lymphoma (MZL)currently, applications for listing of R2 for recurrent/incurable FL and MZL are under review by the EuropeanMedicines(http://AuthorityIn addition, Shinji has submitted a supplementary application for The R2 program to treat recurrent/incurable inert B-cell NHL to Japanese regulatorsThis approval is based on positive data from Phase III research on AUGMENTThis is a randomized, double-blind, international clinical study that assesses the efficacy and safety of R2 protocols in previously treated FL and MZL patients, and compares them with placebo-litosionestudy a total of 358 patients, including FL 295 cases, MZL 63 cases, these patients received at least one system therapy, the disease relapse or difficult to treat, but not on the rituxima monoantigenThe results showed that the Non-Progression Life (PFS) in the R2 Treatment Group achieved a statistically significant improvement (median PFS: 39.4 months vs 14.1 months, HR : 0.46, 95% CI: 0.34-0.62, p 0.0001) achieved the primary endpoint of the studyData for the median follow-up of 28.3 months (range: 0.1-51.3 months) showed that in terms of total lifetime (OS), the R2 treatment group observed a positive trend of numerical improvement (HR ?0.61, 95% CI: 0.33-1.13), but did not achieve a statistically significant differenceIn terms of safety, the safety of the R2 scheme is consistent with the known safety of
    the drug(http:// , and no new safety signals are found Adverse reactions reported in FL/MZL patients treated with R2 included: neutrophil reduction (58%), diarrhea (31%), constipation (26%), cough (24%), fatigue (22%), rash (22%), fever (21%), white blood cell reduction (20%), itching (20%), upper respiratory tract infection (18%), abdominal pain (18%), anemia (16%), headache (15%)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.